Stem cells

1. Biological foundations and potency

A stem cell is an unspecialised cell that can produce more stem cells through self-renewal and generate specialised descendants through differentiation. These properties support development, replace short-lived cells and repair some tissues. Stem cells reside in a local microenvironment called a niche, where neighbouring cells, extracellular structures and chemical signals influence whether they remain inactive, divide or differentiate. Not every dividing cell is a stem cell: many progenitor cells have only limited renewal capacity.

Potency describes the range of cell types a cell can generate. Totipotent cells, represented by the zygote and very early embryonic blastomeres, can contribute to both the embryo and extra-embryonic tissues needed for development. Pluripotent cells can generate derivatives of ectoderm, mesoderm and endoderm, the three embryonic germ layers, but lack the complete developmental potential of totipotent cells.

Multipotent stem cells produce several related cell types within a tissue or lineage. Haematopoietic stem cells generate the different blood-cell lineages, including red blood cells, white blood cells and platelets through intermediate progenitors. Unipotent stem cells produce one specialised lineage while retaining self-renewal. Potency and source are different classifications: a cell’s anatomical origin does not, by itself, establish its full differentiation capacity.

• Ectoderm gives rise to structures such as the nervous system and epidermis.
• Mesoderm produces tissues including muscle, bone and blood; endoderm forms epithelial components of organs such as the intestine, liver and pancreas.

2. Major sources and modern biotechnology

Embryonic stem cells are conventionally derived from the inner cell mass of a blastocyst, an early developmental stage reached roughly five to six days after fertilisation. They are pluripotent and can proliferate extensively under suitable laboratory conditions. Their conventional derivation involves destruction of the embryo, creating ethical concerns. Embryonic stem-cell lines are distinct from fetal stem cells obtained from tissues at later developmental stages.

Adult or somatic stem cells occur in tissues such as bone marrow, skin and intestine. They generally have a more restricted differentiation range than embryonic stem cells. Haematopoietic stem cells can be obtained from bone marrow, mobilised peripheral blood or umbilical-cord blood collected after birth. Cord blood therefore contains clinically valuable blood-forming stem cells, not embryonic stem cells. Cord tissue contains different cell populations and should not be treated as interchangeable with cord blood.

Induced pluripotent stem cells, or iPSCs, are produced by reprogramming differentiated cells, such as skin fibroblasts, using defined factors. The classical factors are OCT4, SOX2, KLF4 and c-MYC. Mouse iPSCs were reported in 2006 and human iPSCs in 2007. Reprogramming avoids deriving cells directly from embryos, but does not eliminate concerns about genetic stability, tumour formation or manufacturing quality.

Somatic cell nuclear transfer is a different technique: the nucleus of a body cell is introduced into an enucleated egg. Deriving stem cells from the resulting early embryo is associated with therapeutic cloning, whereas implantation to produce an organism constitutes reproductive cloning. Producing iPSCs does not require this nuclear-transfer procedure.

3. Applications: established treatment versus research

Haematopoietic stem-cell transplantation, often called bone-marrow transplantation even when another cell source is used, is established for selected conditions. These include certain leukaemias, lymphomas, aplastic anaemia, thalassaemia and inherited immune deficiencies. Treatment selection depends on diagnosis, disease stage, donor availability and the patient’s condition. In some indications, transplantation offers the possibility of cure, but it carries substantial risks and is not appropriate for every patient.

An autologous transplant uses the patient’s own cells; an allogeneic transplant uses donor cells. Human leukocyte antigen, or HLA, matching is particularly important for allogeneic transplantation. Donor immune cells may attack the recipient’s tissues, causing graft-versus-host disease. Conversely, donor immune activity can help eliminate residual malignant cells through a graft-versus-leukaemia effect.

Research applications extend beyond transplantation. Patient-derived iPSCs enable disease modelling and testing of drug effectiveness or toxicity. Stem-cell-derived organoids are three-dimensional models that reproduce selected structural or functional features of organs, rather than complete miniature organs. Researchers also combine gene correction with stem-cell technologies to investigate inherited disorders.

Regenerative approaches involving pancreatic beta cells, dopamine-producing neurons, heart muscle and retinal cells are at different stages of development. Progress in one cell product or disease does not validate all treatments marketed as stem-cell therapy. Mesenchymal stromal cells, frequently advertised as mesenchymal stem cells, should not be assumed to regenerate any tissue into which they are injected.

4. Safety, ethics and cord-blood banking

Major technical challenges include obtaining the intended cell type, removing unwanted cells, maintaining genetic stability and ensuring survival and integration after transplantation. Residual undifferentiated pluripotent cells can form teratomas, tumours containing multiple tissue types. Other hazards include contamination, immune rejection, inappropriate tissue formation and adverse effects of conditioning chemotherapy. Patient-derived cells are not automatically safe simply because they are autologous.

Ethical issues include the moral status of embryos, informed consent from donors, privacy of genetic information, commercial exploitation and equitable access. Egg procurement for research also raises concerns about donor safety and undue inducement. Consent for donating biological material should distinguish research use from clinical treatment and explain foreseeable commercial uses.

Cord-blood banking preserves haematopoietic stem cells. Public banks make donated units available to suitably matched recipients, while private banks generally store units for a family’s potential use. Routine private banking as universal biological insurance has limitations: a child’s own cord blood may carry the same inherited defect and may be unsuitable for treating certain diseases. Directed storage can be more relevant where a family member has a recognised transplant indication.

5. Indian governance and examination relevance

The Indian Council of Medical Research and the Department of Biotechnology jointly issued the National Guidelines for Stem Cell Research in 2017. These classify research as permissible, restricted or prohibited and provide for specialised institutional oversight through an Institutional Committee for Stem Cell Research, alongside ethics review. Research permission is not equivalent to approval for routine clinical treatment.

The guidelines identify haematopoietic stem-cell transplantation for recognised indications as established care and caution against presenting other investigational applications as proven therapy. Clinical research must follow applicable ethical requirements and regulatory permissions. The Central Drugs Standard Control Organisation regulates relevant clinical trials and products under India’s drug regulatory framework, including the New Drugs and Clinical Trials Rules, 2019.

Important prohibitions under the 2017 guidelines include human reproductive cloning and in-vitro culture of an intact human embryo beyond 14 days after fertilisation or formation of the primitive streak, whichever is earlier. For examination questions, avoid three common assumptions: all stem cells are pluripotent, all stem-cell procedures involve embryos, and all commercially offered stem-cell treatments are scientifically validated.

Previous year questions

No source-linked PYQ is available here yet. Use the practice questions below.

Practice questions